In this episode, Vivienne Parry introduces the EASD Rising Stars of 2025, four early-career researchers whose work spans exercise physiology, precision diabetes medicine, childhood obesity, and metabolic biology. Dr Sindre Lee-Ødegård (Norway) explores exercise as medicine for highrisk groups; Dr Martin Schön (Slovakia/Germany) works on precision diabetes diagnosis and lifestyle interventions; Dr Cadenas-Sánchez (Spain) investigates childhood obesity and brain health; and Dr Jens Lund (Denmark) uncovers how metabolites like lactate act as powerful signaling molecules. From exercise as medicine to precision diabetes care, childhood obesity, and molecular metabolism, these young scientists are redefining how we understand, prevent, and treat diabetes.Together, they reflect on their research journeys, their ambitions for the next decade, and the challenges facing young scientists today. Join us for an inspiring look at the next generation shaping the future of diabetes research and care. #EASD2025 #DiabetesResearch #RisingStars #FutureOfScience #ExerciseMedicine #PrecisionDiabetes #ChildhoodObesity #Metabolism #YoungScientists #Podcast

In this episode, Dr. Viswanathan Mohan, recipient of the inaugural EASD Global Impact Prize, reflects on his remarkable 50-year career transforming diabetes care in India and worldwide. From pioneering diabetes as a medical speciality and training over 29,000 educators, to leading translational research and nationwide screening initiatives, Dr. Mohan’s work has set new benchmarks in global health impact. He discusses the evolving causes of India’s diabetes epidemic, from genetics and high-carbohydrate diets to pollution and urbanisation, and the policies needed to address them. Dr. Mohan also explores how innovation, affordability, and access to technologies like continuous glucose monitoring (CGM) can bridge the care gap for millions, and shares his enduring hope for a future cure for type 1 diabetes. Join us to learn how one physician’s lifelong mission continues to inspire global change in diabetes prevention and treatment.

In this episode, EASD TV host Vivienne Parry sits with Prof. Mikael Rydén (Karolinska Institute), recipient of the 40th Camillo Golgi Prize, about his groundbreaking research on adipose tissue. Prof. Rydén shares insights into how different fat cell subtypes influence disease progression, particularly in diabetes and obesity. His work highlights the potential of precision medicine in tailoring treatments based on the composition of adipose tissue, shifting the focus from generalised treatments to more personalised approaches. Join us for a deep dive into how Prof. Rydén’s research is revolutionising diabetes care and what it means for the future of metabolic health.

In this episode, Dr Teresa Mezza, recipient of the 2025 EASD Minkowski Prize, takes listeners inside her pioneering research on the early mechanisms of type 2 diabetes. As both a clinician and researcher at the Fondazione Policlinico Universitario A. Gemelli in Rome, Dr Mezza studies patients before and after partial pancreatectomy, offering a unique perspective on beta cell adaptation, function, and decline. Her work is revealing early biomarkers that could identify individuals at risk of diabetes - even before hyperglycaemia develops - paving the way for earlier intervention and prevention. Dr Mezza also discusses the importance of translational research, the challenges facing young scientists, and her belief that perseverance and curiosity are the driving forces of meaningful discovery. Join us for this inspiring conversation about science, mentorship, and the future of diabetes research.

In this episode, EASD host, Vivienne Parry sits down with 2025 EASD Claude Bernard Prize recipient, Prof. Andrew Hattersley, to reflect on his career which has transformed diabetes research and care worldwide. From the discovery of key genetic mutations in maturity onset diabetes of the young (MODY) and neonatal diabetes to establishing a global genetic testing programme that has helped patients in more than 100 countries, Prof. Hattersley has shaped our understanding of diabetes. Tune in to hear reflections on his early breakthroughs, the team collaborations that made them possible, and the far-reaching clinical impact of precision medicine for children and families worldwide. Looking to the future, he explores the next frontier: bringing personalised approached into type 2 diabetes care.

In this episode, we meet Prof Gerald Shulman, recipient of this year’s EASD-Novo Nordisk Foundation Diabetes Prize for Excellence, whose pioneering research has reshaped our understanding of insulin resistance and its role in type 2 diabetes and beyond. Prof. Shulman shares insights from over four decades of research into how ectopic lipid accumulation disrupts insulin signalling, leading to diabetes, fatty liver disease, cardiovascular complications, cancers, and Alzheimer’s disease. He explains how his discoveries - from the role of diacylglycerols to innovative mitochondrial-targeted therapies now in clinical trials - could mark a paradigm shift in the treatment of insulin resistance. Join us for this inspiring conversation on the future of metabolic medicine and the exciting prospect of treating insulin resistance as a central target for preventing chronic disease.

In this special episode, host Vivienne Parry is joined by experts Anna Krook (Karolinska Institute), Klemen Dovč (Ljubljana University Medical Centre), Peter Gillard (University Hospital Leuven), and Julia Mader (University of Graz) to explore the rapid evolution of diabetes technology. From continuous glucose monitors (CGMs) and automated insulin delivery (AID) systems to AI-powered apps and integrated health records, the panel discusses how these innovations are transforming care and what barriers remain. They unpack emerging trends in personalisation, device standardisation, and the urgent need for equitable access to ensure no one is left behind. The conversation draws on insights from Diabetologia’s 60th Anniversary Technology Supplement and Symposium (the official journal of the EASD), along with reflections from people living with diabetes themselves. The panel also explores a central question: how do we ensure everyone, from preschoolers to older adults, in both urban and rural settings, can benefit from these technologies? Tune in to hear what’s next for diabetes tech, and why centring people with diabetes in innovation is critical.

In this episode, Dr Andreas Birkenfeld (Germany) and Dr Viswanathan Mohan, 1st EASD Diabetes Global Impact Prize winner (India), join host Vivienne Parry to explore the growing importance of recognising, screening and managing pre-diabetes on a global scale. They discuss how moving beyond diabetes remission to pre-diabetes remission could prevent long-term complications, and why strategic, risk-based screening could ease the economic burden on health systems. From policy change and health economics to public awareness and culturally tailored approaches, this episode highlights why proactive intervention in pre-diabetes is critical and what it will take to make it happen worldwide.

What does the future hold for people living with diabetes? In this episode, our host Vivienne Parry together with diabetes advocates Bastian Hauck, Renza Scibilia and Christian Collin dives into recent advances in diabetes prevention, screening, and therapeutics - from GLP-1 drugs to innovative community-driven screening strategies. But as science accelerates, can our health systems and societies keep up? Join us for an eye-opening conversation on equity, access, and the power of community in reshaping diabetes care.

In this lively episode of Diabetes Insights, Prof. Francesco Rubino (King’s College London) and Dr. Louis Aronne (Weill Cornell Medicine) join Vivienne Parry to debate one of the biggest questions in obesity care: will next-generation medications make bariatric surgery obsolete? Drawing on decades of clinical experience and new trial evidence, they explore whether powerful GLP-1-based therapies and combination drugs can rival the life-changing outcomes of surgery. From costs and complications to patient preferences and the hidden biology of obesity, they unpack how a new era of multi-modal treatment is reshaping care. 🎧 Tune in for sharp insights, respectful disagreement and a glimpse into the future of integrated obesity management. #diabetes #Obesity #GLP1 #BariatricSurgery #Podcast

In this episode, Dr. Melissa Thomas (Eli, Lilly & Company), Dr. Elizabeth Niemoller (Sanofi) and Prof. Michele Solimena (Helmholtz Zentrum München & Technical University of Dresden) join host Vivienne Parry to examine how partnerships between academia and industry are transforming diabetes research and care. They discuss the culture shift from cautious collaboration to dynamic, mission-driven partnerships and how initiatives like INNODIA and the Innovative Medicines Initiative (IMI) are delivering real progress for patients. From translational breakthroughs to embedding patient advocates in clinical trial design, they explore why diverse perspectives, early regulatory foresight and shared goals are essential to accelerating therapeutic innovation. 🎧 Listen now for an insider’s look at how public-private partnerships are redefining diabetes science.

Today on Diabetes Insights, Prof. Raphael Scharfmann (INSERM, France) and Dr. Valeria Sordi (San Raffaele Diabetes Research Institute, Italy) join our host, Vivienne Parry to discuss the progress and remaining challenges in creating functional, insulin-producing beta cells from stem cells. From the fundamental biology of pancreatic development to translational protocols for generating clinical-grade cells, our experts highlight how far the field has advanced and what hurdles remain before cell replacement therapies become a routine option for people with diabetes. They explore key questions around immune rejection, scalability, long-term viability of transplanted cells, and how the research community is navigating the complexities of cell manufacturing at clinical scale. Listen now for a fascinating look at how cutting-edge science is shaping the future of cell-based therapies in diabetes care.

In this episode, Professors Hood Thabit (University of Manchester, UK) and Helen Murphy (University of East Anglia, Norwich, UK) join Vivienne Parry and EASD to discuss the opportunities and persistent challenges in diabetes care in hospitals and pregnancy. The conversation examines how diabetes technology - from continuous glucose monitoring (CGM) to hybrid closed-loop systems - is improving outcomes for people with diabetes in inpatient settings and for pregnant women with type 1 diabetes. The guests reflect on recent advances, national implementation success stories from the NHS, and gaps that still exist in gestational and type 2 diabetes care. A compelling discussion on the balance between innovation, infrastructure, and integrated care. #Diabetes #Type1Diabetes #GestationalDiabetes #CGM #InpatientCare #PregnancyCare #DigitalHealth #Podcast

In this episode, we explore the fascinating history, fall, and resurgence of GIP (glucose-dependent insulinotropic polypeptide) in diabetes therapy. Once overshadowed by GLP-1, GIP is now back in the spotlight, thanks to dual and triple agonist therapies like tirzepatide. Experts discuss how GIP signaling in the brain may influence appetite and weight regulation, why early studies underestimated its therapeutic value, and what the future holds for multi-agonist drug development in metabolic disease. Join Prof. Michael Nauck from the University of Bochum, Dr. Alice Adriaenssens from UCL and our host, Vivienne Perry as they revisit the incretin story, unpack recent breakthroughs in GIP biology, and offer a glimpse into the next wave of gut hormone-based therapies that go beyond glucose control to address obesity and energy expenditure.

In this episode, we explore the evolving world of cell therapy in type 1 diabetes. Professor James Shaw (Newcastle University), Dr Timothy Kieffer (University of British Columbia & Fractal Health), and Dr Trevor Reichman (University of Toronto) join EASD to discuss the established role of islet transplants and the exciting promise of stem cell–derived islets. The conversation covers the clinical realities of pancreas and islet cell transplants, the challenges of immunosuppression, and how scalable, gene-edited stem cell therapies could shape the future of diabetes care. From early trial successes to the potential of immune-evasive cells and gene therapies for GLP-1 delivery, today's episode examines what’s possible today and what’s coming next.

Today’s episode is special, as the topic was requested by members of the Early Career Academy. The spotlight is on work-life balance in academic medicine and research. Dr Anna Krook from the Karolinska Institute in Sweden and Dr Benoit Gauthier from the Andalusian Molecular Biology and Regenerative Medicine Centre – CABIMER with the Ministry of Health of Andalusia in Spain, delve into the critical topic of work-life balance for everyone but specifically, early career academics. Listen in as they discuss the unique challenges faced during this demanding period, including securing grants, managing teaching responsibilities, and navigating personal relationships. The conversation highlights the importance of supportive partnerships, mentorship, and effective delegation. Practical advice is shared on prioritizing tasks, communicating needs, and finding strategies for maintaining well-being amidst the pressures of academic life. #Diabetes #earlycareer #Worklifebalance #research #podcast

In this episode Diabetes Perspectives, Prof. Partha Kar, National Specialty Advisor for Diabetes with NHS England, shares how the UK became the first country in the world to offer universal access to continuous glucose monitors and hybrid closed-loop systems for people with type 1 diabetes. Prof. Kar discusses the challenges of clinical inertia, the crucial role of patient advocacy, and how data-driven outcomes persuaded policymakers to invest in diabetes technology. He also offers lessons for healthcare leaders worldwide and explains why success isn’t just about funding but about listening to those living with the condition. Join us for a practical, inspiring conversation about driving real change in healthcare systems.

In this episode, Prof. Emma Ahlqvist (Lund University) and Prof. Matthias Blüher (University of Leipzig) join host Vivienne Parry to explore the future of type 2 diabetes. They unpack the shift from a one-size-fits-all approach to one that embraces stratified and personalised care. From using machine learning to define diabetes subtypes to applying AI tools for screening, they share how new approaches could enable earlier diagnosis, better treatment choices, and improved outcomes. With obesity increasingly recognised as a chronic disease and not merely a lifestyle issue, they also discuss the need for broader access to therapies - and how stigma continues to stand in the way of effective treatment. Join us for an inspiring glimpse into what diabetes care could look like by 2034. #DiabetesCare #Type2Diabetes #PersonalisedMedicine #AI

In this episode of Diabetes Insights, we’re talking about a topic that doesn’t get nearly enough attention in diabetes care: Sexual Health. Studies show that people with diabetes are twice as likely to experience sexual dysfunction, yet many patients and healthcare professionals struggle to discuss it openly. Join host Vivienne Parry as she speaks with Dr. Aleksandra Uruska, a diabetologist from Poznań University of Medical Sciences, and Dr. Marieke Dewitte, a clinical psychologist and sexologist from Maastricht University. Together, they explore the biological, psychological, and social factors affecting sexual health in diabetes, the importance of breaking the stigma, and how healthcare providers can better support patients in addressing these challenges.

Could weight loss be the key to managing heart failure? In this episode of Diabetes Insights, we dive into the STEP-HFpEF trial, a groundbreaking study exploring the role of GLP-1 receptor agonists in heart failure with preserved ejection fraction (HFpEF). Host Vivienne Parry speaks with Prof. Melanie Davies (University of Leicester), Prof. Mark Petrie (University of Glasgow), and Prof. Mikhail Kosiborod (Saint Luke’s Mid America Heart Institute, USA) about the link between obesity, diabetes, and HFpEF, and how weight management could transform heart failure treatment. With trials already in motion to explore prevention, could we stop HFpEF before it starts? Join us for this insightful conversation on targeting obesity to treat heart failure.